endTB

@PIH, @MSF & @IRDglobal. A new partnership to change MDR-TB treatments around the world.

[endTB @endTB]

The endTB-Q clinical trial results represent a major advancement in the treatment of pre-XDR-TB. Read more here 👉https://t.co/MQ1n8cA1EP
@MSFsci @PIH @IRDGlobal @UNITAID #TB

[endTB @endTB]

Important conclusions transpire from the results of the endTB-Q clinical trial. Read more here >> https://t.co/MQ1n8cA1EP

@MSFsci @PIH @IRDGlobal @UNITAID #TB #UnionConf

[endTB @endTB]

MAJOR NEWS: the endTB-Q clinical trial results are in! They were just presented at the #UnionConf, in Bali. Read the full press release here>>https://t.co/MQ1n8cA1EP

@MSFsci @PIH @IRDGlobal @UNITAID

[endTB @endTB]

The endTB-Q clinical trial results represent a major advancement in the treatment of pre-XDR-TB. Read more here 👉https://t.co/MQ1n8cA1EP
@MSFsci @PIH @IRDGlobal @UNITAID #TB

[endTB @endTB]

Reminder: the presentation of the endTB-Q clinical trial results is happening tomorrow at the #UnionConf in Bali! More here👉https://t.co/Y6w3ILl9dB. And stay tuned for details about the results of this groundbreaking trial!
@MSFsci @PIH @IRDGlobal @UNITAID

[endTB @endTB]

📢The results of the endTB-Q clinical trial, which assesses the safety and efficacy of a new and shorter regimen for the treatment of pre-XDR-TB, will be presented for the first time at the #UnionConf in Bali on Nov 13.👉https://t.co/Y6w3ILl9dB
@MSFsci @PIH @IRDGlobal @UNITAID

[endTB @endTB]

📢 Breaking news: in a rapid communication, the WHO recommended 3 new, shorter, more tolerable regimens for MDR/RR-TB, which were studied in the endTB clinical trial! More details 👉https://t.co/mhNCywPjLM
@MSFsci @PIH @IRDGlobal @UNITAID

[endTB @endTB]

The endTB consortium partners are happy to report that the last visit for the last study participant in the endTB-Q trial was completed on 22 July! Read more: https://t.co/FKwuenGz3A
@MSFsci @PIH @IRDGlobal @UNITAID

[endTB @endTB]

🌟Join us on May 23, for #EpicentreScientificDay! Maelenn Gouillou, Biostatistician of the endTB project, will present findings on drug-resistant tuberculosis subgroups from the #endTB clinical trial.

Don't miss it at 2:15pm at Salons de l'Aveyron in Paris.

More info here👇🏾

[Epicentre_MSF @Epicentre_MSF]

📢 D-1 month before the Scientific Day!
Ready to dive in? TB experts will be on hand to discuss DIAGNOSIS and TREATMENT, highlighting the challenges and solutions for the most vulnerable populations, in particular, children!
Registration 👉🏾 https://t.co/avjoc4uLeG

[endTB @endTB]

🌟 Exciting news! Today at #ESCMIDGlobal2024, Dr. Lorenzo Guglielmetti, Director of the #endTB project, will be presenting a groundbreaking comparison of efficacy and safety between experimental regimens for MDR-TB from the endTB clinical trial (Hall H, 13:30-15:30).

[ESCMID @ESCMID]

Ready for day 4 of #ESCMIDGlobal2024? While it is the final day, the fun is not over yet. We have plenty of symposiums, sessions and talks lined up. Whether you're joining onsite or remotely, tell us what is on your agenda today? Thank you for you the incredible turnout!

[Doctors Without Borders (MSF) Southern Africa @MSF_southafrica]

The @EndTB trial results increase patient-centred treatment options for RR/MDR-TB with three shortened, all-oral, noninferior regimens to a current well-performing standard of care. #MSFSciDaysSA2024
More details 👉https://t.co/4t3Vgk2NXt

[endTB @endTB]

Save the date! 🚀

The MSF Scientific Days Southern Africa 2024 are starting tomorrow, Wed. April 17.

We thank Dr. Kunda Mikanda, Principal Investigator of the endTB Clinical Trials site in Lesotho, who will present the results of the trial on improving the treatment of MDR-TB.

[Head Of Mission - Djoki Bahati @MSF_EswatiniHoM]

The MSF in Eswatini team is eagerly looking forward to the forthcoming MSF Scientific Days Southern Africa 2024 event, scheduled for April 17, 2024.
This full-day event will be an opportunity for us to disseminate knowledge on various topics such as sexual health, tuberculosis,

[IRD Global @IRDGlobal]

Joining hands for #WTBDay 2024, the endTB trial community met at IRD’s Community Dissemination Event.

They celebrated their contribution in advancing knowledge for the treatment of MDR-TB.

@PIH @MSF @UNITAID

#irdglobal #tuberculosis

1/2.

[endTB @endTB]

On this #WorldTBDay24 , join #endTB in celebrating last year’s achievements in the fight against multidrug-resistant #tuberculosis.

Check out our latest news and results: https://t.co/XPON8NteIZ and https://t.co/2mLFCbNd16

@MSF_france @IRDGlobal @PIH @UNITAID @UCSF

[John Green @sportswithjohn]

Premiering now: MASSIVE tuberculosis news. https://t.co/nLjmSbTqNI

[endTB @endTB]

.@IRDGlobal @MSF @PIH , and funder @UNITAID would like thank all those who attended the endTB clinical trial results presentations at the #UnionConf this week! Safe travels home and stay tuned!

[endTB @endTB]

Join us today at 6pm CET at the #UnionConf Community Connect session where researchers will share the #endTB trial results with communities! @MSFsci @IRDGlobal @PIH @UNITAID

[endTB @endTB]

@MSF @PIH @IRDGlobal @UNITAID “Our results offer hope to those in dire need and underscore the urgency of continued research and innovation to address diseases that too often strike the most vulnerable among us", says Carole Mitnick, @PIH Director of Research for #endTB

[endTB @endTB]

.@MSF @PIH @IRDGlobal, and funder @UNITAID are proud to announce that the endTB trial results are out! This landmark trial offers multiple new shortened, all-oral drug regimens to treat adults and children with #MDRTB. Read our press release and more here: https://t.co/p3pfCWJMxW

[endTB @endTB]

@MSF @PIH @IRDGlobal @UNITAID The #endTB trial found 3 new drug regimens delivering similar efficacy & safety to conventional treatments while reducing treatment time by up to two-thirds. 
The trial also adds a 4th regimen as an alternative for people who cannot tolerate some TB drugs. https://t.co/v82AdVcm0L